Peter is CSO of Samsara Therapeutics, the world leading biotech in autophagy therapeutics, a vital cellular process which is implicated in longevity and many diseases including neurodegeneration. He spent more than a decade at Sanofi, in various global discovery and business development roles. He and his teams have contributed to the advancement of many projects into development across multiple therapeutic areas. He started his career at AstraZeneca after postdoctoral studies at the University of Pennsylvania, a PhD from Cambridge University, and a BSc in Chemistry from Imperial College London.  He holds an MBA from the University of Bath.